Optical Genome Mapping Reveals and Characterizes Recurrent Aberrations and New Fusion Genes in Adult ALL
- PMID: 36980958
- PMCID: PMC10048194
- DOI: 10.3390/genes14030686
Optical Genome Mapping Reveals and Characterizes Recurrent Aberrations and New Fusion Genes in Adult ALL
Abstract
(1) Background: In acute lymphoblastic leukemia (ALL) the genetic characterization remains challenging. Due to the genetic heterogeneity of mutations in adult patients, only a small proportion of aberrations can be analyzed with standard routine diagnostics. Optical genome mapping (OGM) has recently opened up new possibilities for the characterization of structural variants on a genome-wide level, thus enabling simultaneous analysis for a broad spectrum of genetic aberrations. (2) Methods: 11 adult ALL patients were examined using OGM. (3) Results: Genetic results obtained by karyotyping and FISH were confirmed by OGM for all patients. Karyotype was redefined, and additional genetic information was obtained in 82% (9/11) of samples by OGM, previously not diagnosed by standard of care. Besides gross-structural chromosome rearrangements, e.g., ring chromosome 9 and putative isodicentric chromosome 8q, deletions in CDKN2A/2B were detected in 7/11 patients, defining an approx. 20 kb minimum region of overlap, including an alternative exon 1 of the CDKN2A gene. The results further confirm recurrent ALL aberrations (e.g., PAX5, ETV6, VPREB1, IKZF1). (4) Conclusions: Genome-wide OGM analysis enables a broad genetic characterization in adult ALL patients in one single workup compared to standard clinical testing, facilitating a detailed genetic diagnosis, risk-stratification, and target-directed treatment strategies.
Keywords: CDKN2A/B deletion; adult acute lymphoblastic leukemia (ALL); isodicentric chromosome; optical genome mapping (OGM); ring chromosome.
Conflict of interest statement
V.N.-E. received travel support and congress registration fees from Jazz Pharmaceuticals. D.B.V. received speaker’s honoraria from Roche, Bristol Myers Squibb and Pfizer, consultant’s honoraria from Pfizer, Bristol Myers Squibb and Gilead as well as travel support and congress registration fees from Gilead, Abbvie and Celgene. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures
References
-
- National Cancer Institute Adult Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version. [(accessed on 20 September 2022)]; Available online: https://www.cancer.gov/types/leukemia/hp/adult-all-treatment-pdq.
-
- Leukemia and Lymphoma Society ALL Subtypes|Leukemia and Lymphoma Society. [(accessed on 20 September 2022)]. Available online: https://www.lls.org/leukemia/acute-lymphoblastic-leukemia/diagnosis/all-....
-
- Gökbuget N., Baldus C., Brüggemann M., Hauswirth A.W., Schanz U., Machherndl-Spandl S., Stelljes M., Topp M. Akute lymphatische Leukämie (ALL): Onkopedia Leitlinien. [(accessed on 20 September 2022)]. Available online: https://www.onkopedia.com/de/onkopedia/guidelines/akute-lymphatische-leu....
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous
